Igraine (AQSE:KING) Tax Rate % : 0.00% (As of . 20)

View and export this data going back to 2008. Start your Free Trial

What is Igraine Tax Rate %?

Tax Rate % is calculated as Tax Expense divided by its Pre-Tax Income. Igraine's Tax Expense for the six months ended in . 20 was £0.00 Mil. Igraine's Pre-Tax Income for the six months ended in . 20 was £0.00 Mil. Therefore, Igraine's Tax Rate % for the quarter that ended in . 20 was 0.00%.

Igraine Tax Rate % Historical Data

The historical data trend for Igraine's Tax Rate % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Igraine Tax Rate % Chart

Igraine Annual Data

Trend

Tax Rate %

Igraine Semi-Annual Data

Tax Rate %

Igraine Tax Rate % Calculation

Tax Rate % is the ratio of tax expense divided by pretax income, usually presented in percent.

Igraine's Tax Rate % for the fiscal year that ended in . 20 is calculated as

Tax Rate %	=	Tax Expense (A: . 20 )	/	Pre-Tax Income (A: . 20 )
	=		/
	=	%

Igraine's Tax Rate % for the quarter that ended in . 20 is calculated as

Tax Rate %	=	Tax Expense (Q: . 20 )	/	Pre-Tax Income (Q: . 20 )
	=		/
	=	%

Igraine Tax Rate % Related Terms

Thank you for viewing the detailed overview of Igraine's Tax Rate % provided by GuruFocus.com. Please click on the following links to see related term pages.

Igraine Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Igraine PLC (AQSE:KING) » Definitions » Tax Rate %

Comparable Companies

Traded in Other Exchanges

N/A

Address

20 Primrose Street, 8th Floor, The Broadgate Tower, London, GBR, EC2A 2EW

Website

https://www.igraineplc.com

Igraine PLC is an investment company. Its business investment is to source and develops breakthrough technologies and commercially attractive discoveries in the health, Medtech, Biotech, and life science sectors.